Home / Stock ratings / Healthcare Stocks / BMY
Stock rating · Pharmaceutical Preparations
Bristol-Myers Squibb Co. (BMY) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Bristol-Myers Squibb Co. 73 out of 100 (Highest Conviction). Its highest factor score is catalyst setup at 94, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-07BMY · composite score
About Bristol-Myers Squibb Co.
Bristol Myers Squibb discovers, develops, and markets drugs across therapeutic areas including cardiovascular disease, cancer, and immune disorders, with a particular emphasis on immuno-oncology drug development. The company generates close to 70% of total sales from the US, a greater reliance on the US market than most of its peers.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How BMY's rating has moved
- 0Past week, since Sep 30: score held at 73.
- -1Past four weeks, since Sep 9: score fell 1 point to 73.
Weekly points: Sep 9: 74 · Sep 16: 74 · Sep 23: 72 · Sep 30: 73 · Oct 7: 73 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why BMY scores 73/100
BMY's 8 factor scores run from 50 to 94, and 3 of them sit above its composite of 73. Here is how BMY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 13.1x vs sector 22.0x median
- Forward P/E 9.1x, earnings growth accelerating
- FCF yield 6.7%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 71%
- ROE 47%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +14%
- Earnings in 22 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 22 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BMY compares
As of October 7, 2026, Bristol-Myers Squibb Co. is tied for 1st of 20 in Healthcare Stocks, where the average score is 67.
Key risks for BMY
- High debt-to-equity ratio 2.0x, rate-sensitive balance sheet
Sector and theme context
Bristol-Myers Squibb Co. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds BMY's momentum and catalyst factors above.
BMY trade plan (Pro)
MELANY has a full position plan for Bristol-Myers Squibb Co.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates BMY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Bristol-Myers Squibb Co.'s 73/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BMY
Is Bristol-Myers Squibb Co. (BMY) a buy?
As of 2026-10-07, MELANY rated Bristol-Myers Squibb Co. Highest Conviction with a composite score of 73/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Bristol-Myers Squibb Co.'s MELANY score?
Bristol-Myers Squibb Co. (BMY) has a MELANY composite score of 73/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BMY stock rating calculated?
MELANY scores BMY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Bristol-Myers Squibb Co. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Bristol-Myers Squibb Co. (BMY) Highest Conviction with a composite of 73/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BMY stock price forecast?
MELANY does not publish price targets or forecasts for BMY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 73/100 across eight factors for Bristol-Myers Squibb Co., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BMY stock overvalued or undervalued?
MELANY's valuation factor currently reads 65/100 for Bristol-Myers Squibb Co., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BMY's read.
What price should I buy BMY at?
Rather than chasing the current price, MELANY computes a smart entry zone for BMY: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying BMY stock?
The top risks MELANY currently flags for Bristol-Myers Squibb Co.: High debt-to-equity ratio 2.0x, rate-sensitive balance sheet. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Bristol-Myers Squibb Co. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 83/100 for Bristol-Myers Squibb Co., and earnings track record, at 90/100. The 73/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BMY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 53/100 for BMY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BMY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BMY continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BMY included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.